Bliss GVS Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Bliss GVS Pharma Ltd. on BSE

Load latest

Bliss GVS Pharma Ltd.

12 May 2025

132.96

-0.15%

Company Update

Bliss GVS Pharma Ltd - 506197 - Intimation Of Book Closure In Accordance With Regulation 42 …

BSE India

According to Section 91 of the Companies Act, 2013 and Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby inform you that the Register of Members and Share Transfer Books of the Company will remain closed from Friday, July 25, 2025 to Thursday, July 31, 2025 (both days inclusive) for 40th AGM.

pdf

Bliss GVS Pharma Ltd.

12 May 2025

132.96

-0.15%

Corp. Note

Bliss GVS Pharma Ltd - 506197 - Corporate Action-Board approves Dividend

BSE India

Declaration of Final Dividend for the Financial Year Ended March 31, 2025.

pdf

Bliss GVS Pharma Ltd.

12 May 2025

132.96

-0.15%

Result

Bliss GVS Pharma Ltd - 506197 - Board Meeting Outcome for Outcome Of The Board Meeting …

BSE India

We would like to inform you that, the Board Meeting of the Company was held today i.e. Monday, May 12, 2025 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the matters amongst others as attached.

pdf

	Mar 2025	Dec 2024	Mar 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	210.05	225.68	203.73	-6.9%	3.1%
Operating Profit Qtr	21.09	29.79	28.35	-29.2%	-25.6%
Net Profit Qtr	15.54	23.80	-9.15	-34.7%	269.8%
Earning Per Share Adjusted latest Qtr	1.47	2.26	-0.87	-35.0%	269.0%

* Consolidated data

Detailed Results

Bliss GVS Pharma Ltd.

12 May 2025

132.96

-0.15%

Company Update

Bliss GVS Pharma Ltd - 506197 - Announcement under Regulation 30 (LODR)-Issue of Securities

BSE India

The Board of Directors in its meeting held today i.e., May 12, 2025, has approved the issuance and allotment of Sweat Equity shares to the members of the Promoter and Promoter Group of the Company.

pdf

Bliss GVS Pharma Ltd.

07 May 2025

132.96

-0.15%

Board Meeting

Bliss GVS Pharma Ltd - 506197 - Update on board meeting

BSE India

Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2025 ,inter alia, to consider and approve Update on board meeting- To consider and approve the proposal for issuance of Sweat Equity Shares. Enclosed herewith please find attached intimation in this regard.

pdf

Bliss GVS Pharma Ltd.

05 May 2025

132.96

-0.15%

Board Meeting

Bliss GVS Pharma Ltd - 506197 - Board Meeting Intimation for Approval Of Audited (Standalone & …

BSE India

Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2025 ,inter alia, to consider and approve a) The Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2025, along with the Statement of Assets and Liabilities, Cash Flow Statement, and take note of the Audit Report with modified opinion, if any, thereon. b) The Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2025, and c) Recommend the Final Dividend, if any, for the financial year ended March 31, 2025

pdf

Bliss GVS Pharma Ltd.

03 May 2025, 10:25AM

132.96

-0.15%

Company Update

Bliss GVS Pharma Ltd - 506197 - Intimation Under Regulation 30 Of SEBI (LODR) Regulation, 2015- …

BSE India

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Bliss GVS Pharma Limited (hereinafter referred to as "the Company") had invoked arbitration proceedings against PAN Pharmaceuticals Limited (Nairobi, Kenya) for recovery of its outstanding dues by way of filing a petition seeking appointment of an arbitrator before the Supreme Court of India. Enclosed herewith please find the intimation in this regard.

pdf

Bliss GVS Pharma Ltd.

30 Apr 2025

132.96

-0.15%

Corp. Note

Bliss GVS Pharma Ltd - 506197 - Format of the Initial Disclosure to be made by …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyBliss GVS Pharma Ltd 2CIN NO.L24230MH1984PLC034771 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 47.59 4Highest Credit Rating during the previous FY BBB+STABLE 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Aditi Bhatt Designation: Company Secretary EmailId: cs@blissgvs.com Name of the Chief Financial Officer: Deepak Sawant Designation: Chief Financial Officer EmailId: deepak.sawant@blissgvs.com Date: 30/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Bliss GVS Pharma Ltd.

22 Apr 2025

132.96

-0.15%

Company Update

Bliss GVS Pharma Ltd - 506197 - Intimation Of Change In Contact Details Of MUFG Intime …

BSE India

Please find attached the Intimation regarding change in contact details of MUFG Intime Private Limited (Formerly known as Link Intime India Private Limited), Registrar and Share Transfer Agent of the Company.

pdf

Bliss GVS Pharma Ltd.

15 Apr 2025

132.96

-0.15%

Company Update

Bliss GVS Pharma Ltd - 506197 - Intimation Under Regulation 30 Of SEBI (LODR) Regulation, 2015.

BSE India

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform you that the Rising Pharma Holdings, Inc. USA, a marketing and distribution partner of bliss GVS Pharma Limited ("the Company") has been granted final approval from the U.S. Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) for its product "Mesalamine Suppositories 1000 mg". The ANDA was submitted through our partner in the USA.

pdf

Is Bliss GVS Pharma Ltd. worth buying?

167 Votes:

Buy 82.04%

Sell 8.38%

Hold 9.58%